AyalewTefferiMD

PubMed

• The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.
  Marissa M Li, Anmol Baranwal, Mark Gurney, Syed Naseem Shah, Aref Al-Kali, Hassan B Alkhateeb, James M Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek A Mang...> ;Blood Advances. 2024 Apr 2
• Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
  Naseema Gangat, Ayalew Tefferi> ;American Journal of Hematology. 2024 Apr 1
• Risk models in myelofibrosis-the past, present, and future.
  Ayalew Tefferi, Alessandro M Vannucchi> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
  Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui> ;American Journal of Hematology. 2024 Apr 1
• 1 citations
  CALR mutation burden in essential thrombocythemia and disease outcome.
  Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Ale...> ;Blood. 2024 Mar 28
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
  Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
• Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.
  Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat> ;Blood Cancer Journal. 2024 Mar 19
• Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?
  Mostafa Abdallah, Kaaren Reichard, Naseema Gangat, Ayalew Tefferi> ;Blood Cancer Journal. 2024 Mar 18
• Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.
  Ayalew Tefferi, Animesh Pardanani> ;Blood Cancer Journal. 2024 Mar 18
• JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?
  Maria Chiara Finazzi, Ayalew Tefferi, Alessandro Rambaldi> ;American Journal of Hematology. 2024 May 1
• Prognostic impact ofmutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
  Farrukh, F., Abdelmagid, M., Mangaonkar, A., Patnaik, M., Al-Kali, A., Elliott, M., Begna, K., Hook, C., Hogan, W., Pardanani, A., Litzow, M., Ketterling, R., Gangat, ...> ;Haematologica. 2024 Mar 7
• Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
  Mrinal M Patnaik, Ayalew Tefferi> ;American Journal of Hematology. 2024 Mar 7
• 1 citations
  New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
  Naseema Gangat, Ayalew Tefferi> ;American Journal of Hematology. 2024 May 1
• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
  Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Mark Litzow...> ;British Journal of Haematology. 2024 Apr 1
• Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
  Baranwal, A., Gurney, M., Basmaci, R., Katamesh, B., He, R., Viswanatha, D., Greipp, P., Foran, J., Badar, T., Murthy, H., Yi, C., Palmer, J., Mangaonkar, A., Patnaik,...> ;Haematologica. 2024 Feb 1
• Incidental discovery of KIT-mutated mastocytoma in a colon polyp.
  Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh Pardanani, Ayalew Tefferi> ;American Journal of Hematology. 2024 May 1
• 3 citations
  One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
  Karrar, O., Ketterling, R., Gangat, N., Al-Kali, A., Begna, K., Elliott, M., Wolanskyj-Spinner, A., Pardanani, A., Hanson, C., Tefferi, A.> ;Blood Cancer Journal. 2024 Jan 18
• EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
  Anmol Baranwal, Abhishek Mangaonkar, Mithun V Shah, Aref Al-Kali, Ayalew Tefferi, William J Hogan, Mark R Litzow, Mrinal M Patnaik, Hassan B Alkhateeb> ;Bone Marrow Transplantation. 2024 Apr 1
• 3 citations
  Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
  Tefferi, A., Pardanani, A., Gangat, N.> ;American Journal of Hematology. 2024 Feb 1
• 3 citations
  Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...
  Karrar, O., Abdelmagid, M., Rana, M., Iftikhar, M., McCullough, K., Al-Kali, A., Alkhateeb, H., Begna, K., Elliott, M., Mangaonkar, A., Saliba, A., Hefazi Torghabeh, M...> ;American Journal of Hematology. 2024 Feb 1
• The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
  Barbui, T., Carobbio, A., Thiele, J., Rumi, E., Rambaldi, A., Vannucchi, A., , Gangat, N., Tefferi, A.> ;Blood Cancer Journal. 2023 Dec 15
• 1 citations
  TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
  Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Pa...> ;British Journal of Haematology. 2024 Apr 1
• 8 citations
  Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive...
  Gangat, N., Karrar, O., Iftikhar, M., McCullough, K., Johnson, I., Abdelmagid, M., Abdallah, M., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Saliba, A., Hef...> ;American Journal of Hematology. 2024 Feb 1
• 1 citations
  Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
  Pardanani, A., Reichard, K., Tefferi, A.> ;British Journal of Haematology. 2024 Feb 1
• 1 citations
  Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
  Kröger, N., Bacigalupo, A., Barbui, T., Ditschkowski, M., Gagelmann, N., Griesshammer, M., Gupta, V., Hamad, N., Harrison, C., Hernandez-Boluda, J., Koschmieder, S., J...> ;The Lancet. Haematology. 2024 Jan 1
• Join now to see all

Abstracts/Posters

• Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytos...
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504...
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neo...
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...
  Ayalew Tefferi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Trainee Didactic Sessions: How to Set Up a Clinical Research Program 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Cancer Medicine and Hematology 
  Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 9/29/2013
• Cancer Medicine and Hematology 
  Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 9/29/2013
• Join now to see all

Other

• Clinical manifestations and diagnosis of primary myelofibrosis 
  Tefferi A
  http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-primary-myelofibrosis
  UpToDate, Wolters Kluwer Health - 2013-01-31
• Approach to the patient with thrombocytosis 
  Tefferi A
  http://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis
  UpToDate, Wolters Kluwer Health - 2012-09-06
• Prognosis and treatment of primary myelofibrosis 
  Tefferi A
  http://www.uptodate.com/contents/prognosis-and-treatment-of-primary-myelofibrosis
  UpToDate, Wolters Kluwer Health - 2013-04-04
• Pathogenetic mechanisms in primary myelofibrosis 
  Tefferi A
  http://www.uptodate.com/contents/pathogenetic-mechanisms-in-primary-myelofibrosis
  UpToDate, Wolters Kluwer Health - 2013-04-12
• Overview of the myeloproliferative neoplasms 
  Tefferi A
  http://www.uptodate.com/contents/overview-of-the-myeloproliferative-neoplasms
  UpToDate, Wolters Kluwer Health - 2013-04-12
• Diagnosis and clinical manifestations of essential thrombocythemia 
  Tefferi A
  http://www.uptodate.com/contents/diagnosis-and-clinical-manifestations-of-essential-thrombocythemia
  UpToDate, Wolters Kluwer Health - 2012-09-06
• Prognosis and treatment of essential thrombocythemia 
  Tefferi A
  http://www.uptodate.com/contents/prognosis-and-treatment-of-essential-thrombocythemia
  UpToDate, Wolters Kluwer Health - 2013-03-12
• Prognosis and treatment of polycythemia vera 
  Tefferi A
  http://www.uptodate.com/contents/prognosis-and-treatment-of-polycythemia-vera
  UpToDate, Wolters Kluwer Health - 2013-03-12
• Diagnostic approach to the patient with polycythemia 
  Tefferi A
  http://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-polycythemia
  UpToDate, Wolters Kluwer Health - 2012-11-09
• Diagnostic approach to the patient with suspected polycythemia vera 
  Tefferi A
  http://www.uptodate.com/contents/diagnostic-approach-to-the-patient-with-suspected-polycythemia-vera
  UpToDate, Wolters Kluwer Health - 2013-01-25
• Join now to see all